Shilpa Gupta, MD, director of Genitourinary Oncology at Cleveland Clinic compares the safety profile of the antibody-drug conjugates (ADCs) sacituzumab govitecan (Trodelvy) and enfortumab vedotin (Padcev). Both ADCs are FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.